A

Applied Therapeutics, Inc. (APLT)

NGM – Real vaqt narxi. Valyuta: USD

0.10

+0.10 (0.00%)

Yopilishda: Feb 2, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

A

Applied Therapeutics, Inc. (APLT)

NGM – Real vaqt narxi. Valyuta: USD

0.10

+0.10 (0.00%)

Yopilishda: Feb 2, 2026, 4:00 PM EDT

03.02.2026

Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics

CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle”) is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; “Applied”), a clinical-stage biopharmaceutical company. Applied's lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Deh.

30.01.2026

Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer

CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.0001 per share of Applied Therapeutics, Inc., a Delaware corporation (“Applied”) for (i) $0.088 per share, net to the seller in cash, without interest, plus (i.

29.01.2026

Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension

NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company” or “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today released the following letter to stockholders regarding the pending tender offer by AT2B, Inc. (“Purchaser”), an indirect wholly owned subsidiary of Cycle Group Holdings Limited (“Cycle”).

29.01.2026

Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer

CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.0001 per share of Applied Therapeutics, Inc., a Delaware corporation (“Applied”) for (i) $0.088 per share, net to the seller in cash, without interest, plus (i.

28.01.2026

Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer

CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.0001 per share of Applied Therapeutics, Inc., a Delaware corporation (“Applied”) for (i) $0.088 per share, net to the seller in cash, without interest, plus (i.

16.12.2025

Here's Why Applied Therapeutics (APLT) Is a Great 'Buy the Bottom' Stock Now

Applied Therapeutics (APLT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

12.12.2025

APLT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Applied Therapeutics, Inc. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Applied Therapeutics, Inc. (NASDAQ: APLT) to Cycle Group Holdings Limited for $0.088 per share in cash plus one non-transferrable contingent value right entitling the holder to receive potential additional payments under certain conditions is fair to Applied shareholders. Halper Sadeh encourages Applied shareholders to click here to learn more about their legal rights and options or co.

Videolar

No Data

There is no data to display

Press-relizlar

03.02.2026

Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics

CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle”) is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; “Applied”), a clinical-stage biopharmaceutical company. Applied's lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Deh.

30.01.2026

Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer

CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.0001 per share of Applied Therapeutics, Inc., a Delaware corporation (“Applied”) for (i) $0.088 per share, net to the seller in cash, without interest, plus (i.

29.01.2026

Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension

NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company” or “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today released the following letter to stockholders regarding the pending tender offer by AT2B, Inc. (“Purchaser”), an indirect wholly owned subsidiary of Cycle Group Holdings Limited (“Cycle”).

29.01.2026

Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer

CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.0001 per share of Applied Therapeutics, Inc., a Delaware corporation (“Applied”) for (i) $0.088 per share, net to the seller in cash, without interest, plus (i.